Synlogic (NASDAQ:SYBX) – Investment analysts at Piper Jaffray upped their Q3 2018 earnings estimates for Synlogic in a research note issued to investors on Tuesday, May 15th. Piper Jaffray analyst E. Tenthoff now forecasts that the biotechnology company will earn ($0.60) per share for the quarter, up from their previous forecast of ($0.61). Piper Jaffray has a “Buy” rating and a $15.00 price objective on the stock. Piper Jaffray also issued estimates for Synlogic’s Q4 2018 earnings at ($0.64) EPS, FY2018 earnings at ($2.38) EPS, Q2 2019 earnings at ($0.74) EPS, Q3 2019 earnings at ($0.77) EPS, Q4 2019 earnings at ($0.82) EPS and FY2019 earnings at ($3.01) EPS.
Synlogic (NASDAQ:SYBX) last announced its earnings results on Tuesday, May 15th. The biotechnology company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.18. The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.21 million.
Shares of Synlogic opened at $9.97 on Friday, according to Marketbeat. The firm has a market cap of $199.44 million, a P/E ratio of -1.70 and a beta of 2.06. Synlogic has a 1-year low of $10.16 and a 1-year high of $10.50.
Several institutional investors have recently added to or reduced their stakes in SYBX. Artal Group S.A. acquired a new position in shares of Synlogic in the fourth quarter valued at approximately $5,335,000. Spark Investment Management LLC bought a new stake in Synlogic in the fourth quarter valued at approximately $105,000. Renaissance Technologies LLC bought a new stake in Synlogic in the fourth quarter valued at approximately $191,000. Deutsche Bank AG boosted its holdings in Synlogic by 204.0% in the fourth quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 13,200 shares during the last quarter. Finally, Texas Treasury Safekeeping Trust Co. bought a new position in shares of Synlogic during the 1st quarter worth approximately $975,000. 56.20% of the stock is owned by institutional investors.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.